Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Toni K. Choueiri"'
Autor:
Primo N. Lara, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Daniel Heinrich, Oleg Nikolaevich Lipatov, Craig Gedye, Erhan Gokmen, Alejandro Acevedo, Andrey Semenov, Se Hoon Park, Rustem Airatovich Gafanov, Fatih Kose, Mark Jones, Xiaoqi Du, Mihaela Munteanu, Rodolfo Perini, Toni K. Choueiri, Robert J. Motzer
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-12 (2024)
Abstract Background Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deoxygenase 1 selective i
Externí odkaz:
https://doaj.org/article/f27c30f1bd8e406580492b76ee1bb216
Autor:
Yufei Wang, Alicia Buck, Brandon Piel, Luann Zerefa, Nithyassree Murugan, Christian D. Coherd, Andras G. Miklosi, Haraman Johal, Ricardo Nunes Bastos, Kun Huang, Miriam Ficial, Yasmin Nabil Laimon, Sabina Signoretti, Zhou Zhong, Song-My Hoang, Gabriella M. Kastrunes, Marion Grimaud, Atef Fayed, Hsien-Chi Yuan, Quang-De Nguyen, Tran Thai, Elena V. Ivanova, Cloud P. Paweletz, Ming-Ru Wu, Toni K. Choueiri, Jon O. Wee, Gordon J. Freeman, David A. Barbie, Wayne A. Marasco
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-16 (2024)
Abstract One of the major hurdles that has hindered the success of chimeric antigen receptor (CAR) T cell therapies against solid tumors is on-target off-tumor (OTOT) toxicity due to sharing of the same epitopes on normal tissues. To elevate the safe
Externí odkaz:
https://doaj.org/article/90de263ab4864245afd1b4be5c061876
Autor:
Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS) and overall survival (OS) versus everolimus in patients with advanced RCC after prior antiangiogenic therapy. Methods In this exploratory analysis,
Externí odkaz:
https://doaj.org/article/08953196fa7443bbb663ea7061737037
Autor:
Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/fb97b853f0ab49559f8e621718cfb4a1